Form 4: Pelthos Therapeutics Director Peter Greenleaf Granted Significant Equity Awards

Pelthos Therapeutics Inc. Director Peter Greenleaf was granted 25,478 restricted stock units and 77,640 stock options, both with an exercise price of $13.50 per share, as part of his compensation.

Summary

• Peter Greenleaf, a Director of Pelthos Therapeutics Inc. (PTHS), was granted equity awards on July 2, 2025.
• The grants include 25,478 restricted stock units (RSUs) and 77,640 stock options.
• Both the RSUs and stock options have an exercise price of $13.50 per share.
• The vesting schedule for both awards begins with an initial one-third (1/3) vesting on July 2, 2025, with the remaining portions vesting in equal quarterly installments over a two-year period.
• The expiration date for both the RSUs and stock options is July 2, 2035.
• Following these transactions, Peter Greenleaf beneficially owns 25,478 restricted stock units and 77,640 stock options directly.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive sign, indicating alignment of interests and a commitment to long-term performance. It's a standard compensation practice.

Positives

• Granting of equity awards to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The awards represent a significant compensation component for Director Peter Greenleaf, potentially enhancing his commitment to the company's success.

Future Outlook

The granted restricted stock units and stock options will vest over a two-year period following an initial one-third vesting on July 2, 2025, indicating a long-term incentive structure for the director.

Industry Context

This transaction is a standard practice in the biotechnology and pharmaceutical industries, where equity grants are commonly used to compensate directors and executives, aligning their interests with long-term company performance and shareholder value creation. Such grants are typical for companies like Pelthos Therapeutics Inc. as they progress through development stages.

Comparison to Industry Standards

• Equity grants to directors, such as restricted stock units and stock options, are a common compensation mechanism across the biotechnology and pharmaceutical sectors, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, which frequently use similar long-term incentive plans to attract and retain talent.
• The vesting schedule, with an initial immediate vesting followed by quarterly installments over two years, is a standard approach designed to ensure continued commitment and performance from the director.
• The exercise price being set at the market price on the grant date is typical for stock options, ensuring they become valuable as the company's stock price appreciates.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: May signal stability and a commitment to attracting and retaining key talent, potentially boosting morale.

Next Steps

• Continued vesting of restricted stock units and stock options on a quarterly basis over the next two years, following the initial vesting on July 2, 2025.
• Potential exercise of stock options by Peter Greenleaf prior to their expiration on July 2, 2035.

Key Dates

Keywords

Pelthos Therapeutics Inc., PTHS, Peter Greenleaf, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership